Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week

NCT00075205 is registered in ClinicalTrials.gov with National Institute on Alcohol Abuse and Alcoholism (NIAAA) as lead sponsor.

NCT NCT00075205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00075205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
March 15, 2007
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol drinking, healthy